Esperion Therapeutics (ESPR) - Total assets

Total assets on the balance sheet as of June 2024 : C$0.47 B

According to Esperion Therapeutics's latest financial reports the company's total assets are C$0.47 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Esperion Therapeutics - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year	Total assets	Change
2023-12-31	C$0.27 B	-18.87%
2022-12-31	C$0.33 B	-30.33%
2021-12-31	C$0.48 B	7.2%
2020-12-31	C$0.45 B	62.04%
2019-12-31	C$0.27 B	42.06%
2018-12-31	C$0.19 B	-43.98%
2017-12-31	C$0.34 B	6%
2016-12-31	C$0.32 B	-19.72%
2015-12-31	C$0.41 B	147%
2014-12-31	C$0.16 B	99.51%
2013-12-31	C$83.29 M	1042.89%
2012-12-31	C$7.28 M	228.69%
2011-12-31	C$2.21 M
2002-12-31	C$81.19 M	-34.94%
2001-12-31	C$0.12 B

Total Assets for similar companies or competitors

Company	Total assets	differencediff.	Country
Ultragenyx RARE	C$2.19 B	359.37%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	C$9.58 B	1,905.89%	🇺🇸 USA
Pfizer PFE	C$293.24 B	61,262.86%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	C$48.94 B	10,142.65%	🇺🇸 USA
Amicus Therapeutics FOLD	C$1.01 B	112.73%	🇺🇸 USA
Lexicon Pharmaceuticals LXRX	C$0.50 B	5.97%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is receiving financial compensation for Delta App installs.
CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions